

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)




(10) International Publication Number
WO 2024/214046 A1

- (51) **International Patent Classification:**
A61P 29/00 (2006.01) *C07D 487/04* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/053566
- (22) **International Filing Date:**
11 April 2024 (11.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/496,053 14 April 2023 (14.04.2023) US
63/515,968 27 July 2023 (27.07.2023) US
- (71) **Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1 Doshomachi 4-chome, Chuoku, Osaka-shi, Osaka 541-0045 (JP).
- (72) **Inventors: MIKAMI, Satoshi;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **HOMMA, Misaki;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **HASUI, Tomoaki;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **TANAKA, Yuta;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **WANG, Chunxiang;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **DAINI, Masaki;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **IMAMURA, Keisuke;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **KIKUCHI, Fumiaki;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **MORIMOTO, Shinji;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **TOITA, Akinori;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **YUKAWA, Takafumi;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **UYGHUR, Dilhumar;** c/o Takeda Pharmaceuti-

cal Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **OHASHI, Tomohiro;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **HIDAKA, Kosuke;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **NAKA-MURA, Shinji;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **FUSHIMI, Makoto;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **WAKABAYASHI, Takeshi;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **YAMAMOTO, Takeshi;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **OYABU, Norio;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **IBANEZ SANCHEZ, Ignacio;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP). **TOYOFUKU, Masashi;** c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa-Shi, Kanagawa 251-0012 (JP).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3



(57) **Abstract:** The invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein L, X, Y, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined in the specification, for treatment of a disease, disorder or condition associated with NLRP3, including a disease, disorder or condition associated with a heterozygous gain of function mutation in the NLRP3 gene such as cryopyrin-associated periodic syndrome (CAPS).

[Continued on next page]

WO 2024/214046 A1

WO 2024/214046 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))